In general, assessment and reporting of the codeletion status should be reserved for cases with IDH1/2 mutations, since it has been shown that 1p19q codeletion status has no impact on the survival of IDH1/2 WT tumors, such as glioblastomas.26 We also detected 1p19q codeletions in over 60% of hypermutated glioma samples, showing that hypermutations do not affect our ability to call 1p19q codeletions from F1/F1CDx. Here, IDH1 is linked to central nervous system cancer.